Abstract
Pulmonary complications are the most common presentations in primary immunodeficiency diseases (PIDs). Treatment of pulmonary manifestations of PIDs varies depending on the underlying processes (e.g., humoral, cellular, combined immunodeficiencies) and etiologies (e.g., infectious, inflammatory, malignant, etc.). The management consists of:
-
(a)
Prophylactic treatments such as chronic antimicrobial therapy; appropriate vaccinations; immunoglobulin supplementation, mainly in humoral or combined humoral and cellular immunodeficiencies; or anti-inflammatory therapy in diseases with airway involvement
-
(b)
Therapeutic management such as appropriate antibiotic coverage for pulmonary infectious manifestations, bronchodilator therapy for obstructive lung disease, airway clearance devices in bronchiectasis, lung transplantation in few cases, and finally bone marrow transplantation as a more definitive therapy in some disorders
-
(c)
Strategies to improve symptoms and overall quality of life, for example, cough suppressants, supplemental oxygen therapy, pulmonary rehabilitation, and nutritional support. Here, we provide an overview of different therapeutic and prophylactic approaches based on the underlying immunologic process.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–60. e4
Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E, et al. Prevention of infections during primary immunodeficiency. Clin Infect Dis. 2014;59(10):1462–70.
Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003;348(24):2416–22.
Marciano BE, Wesley R, De Carlo ES, Anderson VL, Barnhart LA, Darnell D, et al. Long-term interferon-γ therapy for patients with chronic granulomatous disease. Clin Infect Dis. 2004;39(5):692–9.
Margolis DM, Melnick DA, Ailing DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis. 1990;162(3):723–6.
Mouy R, Fischer A, Vilmer E, Seger R, Griscelli C. Incidence, severity, and prevention of infections in chronic granulomatous disease. J Pediatr. 1989;114(4):555–60.
Langley JM, Dodds L, Fell D, Langley GR. Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study 1990-2002. BMC Infect Dis. 2010;10(1):219.
Lanternier F, Barbati E, Meinzer U, Liu L, Pedergnana V, Migaud M, et al. Inherited CARD9 deficiency in 2 unrelated patients with invasive Exophiala infection. J Infect Dis. 2015;211(8):1241–50.
Mansouri D, Adimi P, Mirsaedi M, Mansouri N, Tabarsi P, Amiri M, et al. Primary immune deficiencies presenting in adults: seven years of experience from Iran. J Clin Immunol. 2005;25(4):385–91.
Mansouri D, Adimi P, Mirsaeidi M, Mansouri N, Khalilzadeh S, Masjedi MR, et al. Inherited disorders of the IL-12-IFN-γ axis in patients with disseminated BCG infection. Eur J Pediatr. 2005;164(12):753–7.
Obregon RG, Lynch DA, Kaske T, Newell JD, Kirkpatrick CH. Radiologic findings of adult primary immunodeficiency disorders: contribution of CT. Chest. 1994;106(2):490–5.
McShane PJ, Naureckas ET, Tino G, Strek ME. Non–cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–56.
Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1–i58.
Di Renzo M, Pasqui A, Auteri A. Common variable immunodeficiency: a review. Clin Exp Med. 2004;3(4):211–7.
Driessen GJ, Dalm VA, van Hagen PM, Grashoff HA, Hartwig NG, van Rossum AM, et al. Common variable immunodeficiency and idiopathic primary hypogammaglobulinemia: two different conditions within the same disease spectrum. Haematologica. 2013;98(10):1617–23.
Panigrahi MK. Common variable immunodeficiency disorder-An uncommon cause for bronchiectasis. Lung India. 2014;31(4):394.
Rose ME, Lang DM. Evaluating and managing hypogammaglobulinemia. Cleve Clin J Med. 2006;73(2):133. -7, 40, 43-4
Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy. J Allergy Clin Immunol. 2006;117(4):S525–S53.
Neves PC, Guerra M, Ponce P, Miranda J, Vouga L. Non-cystic fibrosis bronchiectasis. Interact Cardiovasc Thorac Surg. 2011;13(6):619–25.
Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax. 2013;68(8):731–7.
Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J. 2014;44(2):382–93.
Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(7):577.
Tay GT, Reid DW, Bell SC. Inhaled antibiotics in cystic fibrosis (CF) and non-CF bronchiectasis. Semin Respir Crit Care Med. 2015;36:267–86. Thieme Medical Publishers
Eaton T, Young P, Zeng I, Kolbe J. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis. Chron Respir Dis. 2007;4(1):23–30.
Main E, Grillo L, Rand S. Airway clearance strategies in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin Respir Crit Care Med. 2015;36:251–66. Thieme Medical Publishers
Reeves EP, Molloy K, Pohl K, McElvaney NG. Hypertonic saline in treatment of pulmonary disease in cystic fibrosis. Sci World J. 2012;2012:465230.
Reeves EP, Williamson M, O'neill SJ, Greally P, McElvaney NG. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med. 2011;183(11):1517–23.
O’donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest. 1998;113(5):1329–34.
Haworth CS, Bilton D, Elborn JS. Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. Respir Med. 2014;108(10):1397–408.
Tsang K, Tan K, Ho P, Ooi G, Ho J, Mak J, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005;60(3):239–43.
Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Libr. 2009;1:CD000996.
Maimon N, Lipton J, Chan C, Marras T. Macrolides in the treatment of bronchiolitis obliterans in allograft recipients. Bone Marrow Transplant. 2009;44(2):69.
Feldman C. The use of antiinflammatory therapy and macrolides in bronchiectasis. Clin Chest Med. 2012;33(2):371–80.
Tabarsi P, Mirsaeidi M, Karimi S, Banieghbal B, Mansouri N, Masjedi MR, et al. Lymphocytic bronchiolitis as presenting disorder in an undiagnosed adult patient with chronic granulomatous disease. Send to Iran J Allergy Asthma Immunol. 2007;6(4):219–21.
Cha S-I, Fessler MB, Cool CD, Schwarz MI, Brown KK. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J. 2006;28(2):364–9.
Prasse A, Kayser G, Warnatz K. Common variable immunodeficiency-associated granulomatous and interstitial lung disease. Curr Opin Pulm Med. 2013;19(5):503–9.
Tanaka N, Kim JS, Bates CA, Brown KK, Cool CD, Newell JD, et al. Lung diseases in patients with common variable immunodeficiency: chest radiographic, and computed tomographic findings. J Comput Assist Tomogr. 2006;30(5):828–38.
Nicholson AG. Lymphocytic interstitial pneumonia and other lymphoproliferative disorders in the lung. Semin Respir Crit Care Med. 2001;22:409–22. Copyright© 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.:+ 1 (212) 584-4662.
Chase NM, Verbsky JW, Hintermeyer MK, Waukau JK, Tomita-Mitchell A, Casper JT, et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol. 2013;33(1):30–9.
Boursiquot J-N, Gérard L, Malphettes M, Fieschi C, Galicier L, Boutboul D, et al. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol. 2013;33(1):84–95.
Franxman TJ, Howe LE, Baker JR. Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency. J Clin Immunol. 2014;34(7):820–7.
Thatayatikom A, Thatayatikom S, White AJ. Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature. Ann Allergy Asthma Immunol. 2005;95(3):293–300.
Kainulainen L, Varpula M, Liippo K, Svedström E, Nikoskelainen J, Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 1999;104(5):1031–6.
Svobodova T, Mejstrikova E, Salzer U, Sukova M, Hubacek P, Matej R, et al. Diffuse parenchymal lung disease as first clinical manifestation of GATA-2 deficiency in childhood. BMC Pulm Med. 2015;15(1):8.
Chin TW, Stiehm ER, Falloon J, Gallin JI. Corticosteroids in treatment of obstructive lesions of chronic granulomatous disease. J Pediatr. 1987;111(3):349–52.
Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine. 2000;79(3):170–200.
Siddiqui S, Anderson VL, Hilligoss DM, Abinun M, Kuijpers TW, Masur H, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis. 2007;45(6):673–81.
Tafti SF, Tabarsi P, Mansouri N, Mirsaeidi M, Ghajar MAM, Karimi S, et al. Chronic granulomatous disease with unusual clinical manifestation, outcome, and pattern of inheritance in an Iranian family. J Clin Immunol. 2006;26(3):291–6.
Freeman AF, Holland SM. The hyper-IgE syndromes. Immunol Allergy Clin North Am. 2008;28(2):277–91.
Shapiro RS. Malignancies in the setting of primary immunodeficiency: implications for hematologists/oncologists. Am J Hematol. 2011;86(1):48–55.
Salavoura K, Kolialexi A, Tsangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res. 2008;28(2B):1263–9.
Gatei M, Young D, Cerosaletti KM, Desai-Mehta A, Spring K, Kozlov S, et al. ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat Genet. 2000;25(1):115.
Taylor A, Metcalfe J, Thick J, Mak Y. Leukemia and lymphoma in ataxia telangiectasia. Blood. 1996;87(2):423–38.
Cohen JM, Sebire NJ, Harvey J, Gaspar HB, Cathy C, Jones A, et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. Blood. 2007;110(6):2209–14.
Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, et al. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol. 2009;124(6):1152–60. e12
Hill A, Thompson R, Wallwork J, Stableforth D. Heart lung transplantation in a patient with end stage lung disease due to common variable immunodeficiency. Thorax. 1998;53(7):622–3.
Yeatman M, McNeil K, Smith JA, Stewart S, Sharples LD, Higenbottam T, et al. Lung transplantation in patients with systemic diseases: an eleven-year experience at Papworth Hospital. J Heart Lung Transplant. 1996;15(2):144–9.
Kuo CY, Kohn DB. Gene therapy for the treatment of primary immune deficiencies. Curr Allergy Asthma Rep. 2016;16(5):39.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Mansouri, N., Mansouri, D. (2019). Treatment of Pulmonary Manifestations of Primary Immunodeficiency Diseases. In: Mahdaviani, S., Rezaei, N. (eds) Pulmonary Manifestations of Primary Immunodeficiency Diseases . Springer, Cham. https://doi.org/10.1007/978-3-030-00880-2_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-00880-2_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-00879-6
Online ISBN: 978-3-030-00880-2
eBook Packages: MedicineMedicine (R0)